CTCL/ mycosis fungoides

Clinical trials for CTCL/ mycosis fungoides explained in plain language.

Never miss a new study

Get alerted when new CTCL/ mycosis fungoides trials appear

Sign up with your email to follow new studies for CTCL/ mycosis fungoides, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

Light-Activated gel shows promise for rare skin cancer

Disease control Stopped early

This Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treat…

Matched conditions: CTCL/ MYCOSIS FUNGOIDES

Phase 3 • Sponsor: Soligenix • Aim: Disease control

Last updated Jul 15, 2026 00:00 UTC

CTCL/ mycosis fungoides

Get alerted when new CTCL/ mycosis fungoides trials appear

Light-Activated gel shows promise for rare skin cancer